



California State Board of Pharmacy
 2720 Gateway Oaks Drive, Suite 100
 Sacramento, CA 95833
 Phone: (916) 518-3100 Fax: (916) 574-8618
 www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency
 Department of Consumer Affairs
 Gavin Newsom, Governor



**California State Board of Pharmacy
 Department of Consumer Affairs
 Legislation and Regulation Committee Meeting Minutes**

DATE: April 29, 2026

LOCATION: OBSERVATION AND PUBLIC COMMENT IN PERSON:
 California Department of Consumer Affairs
 1625 N. Market Blvd., Hearing Room, First Floor
 Sacramento, CA 95834

PUBLIC PARTICIPATION AND COMMENT FROM REMOTE
 LOCATIONS VIA WEBEX

COMMITTEE MEMBERS

PRESENT: Jessi Crowley, PharmD, Licensee Member, Chair
 Nicole Thibeau, PharmD, Licensee Member (via Webex)
 Jeanette Dong, Public Member
 Maria Serpa, PharmD, Licensee Member

COMMITTEE MEMBERS

NOT PRESENT: Trevor Chandler, Public Member
 Kartikeya "KK" Jha, Licensee Member

STAFF MEMBERS PRESENT: Anne Sodergren, Executive Officer
 Julie Ansel, Deputy Executive Officer
 Corinne Gartner, DCA Staff Counsel
 Shelley Ganaway, DCA Staff Counsel
 Deepi Miller, DCA Staff Counsel (via Webex)
 Julie McFall, Executive Specialist Manager
 Sara Jurens, Public Information Officer

I. Call to Order, Establishment of Quorum, and General Announcements

Chairperson Crowley called the meeting to order at 9:05 a.m. Chairperson Crowley reminded all present that the Board is a consumer protection agency charged with administering and enforcing Pharmacy Law. Where protection of the public is inconsistent with other interests sought to be promoted, the protection of the public shall be paramount.

Dr. Crowley reminded Committee members to remain visible with cameras on throughout the open session of the meeting. Dr. Crowley advised if members needed to temporarily turn off their camera due to challenges with internet connectivity, they must announce the reason for their non-appearance when the camera was turned off.

Chairperson Crowley took roll call. The following members were physically present in Sacramento: Jeanette Dong, Public Member; Maria Serpa, Licensee Member; and Jessi Crowley; Licensee Member. Licensee member Nicole Thibeau participated via Webex. Dr. Thibeau disclosed that no persons over 18 years old were present in the room with them as they participated in the meeting remotely via Webex. A quorum was established.

II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings

Members of the public participating from Sacramento and via Webex were provided the opportunity to provide comments on items not on the agenda; however, no comments were made.

III. Approval of the June 11, 2025, Committee Meeting Minutes

Members were provided the opportunity to provide comments on the draft minutes.

Motion: Approve the June 11, 2025, Legislation and Regulation Committee meeting minutes as presented.

M/S: Serpa/Thibeau

Members of the public located in Sacramento or participating via Webex were provided the opportunity to provide comments; however, no comments were made.

Support: 3

Oppose: 0

Abstain: 1

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Abstain
Jha	Not Present
Serpa	Support
Thibeau	Support

IV. Discussion and Possible Action to Recommend to the Board Positions on Pending Legislation Impacting the Practice of Pharmacy, the Board's Jurisdiction, or Board Operations

Chairperson Crowley noted there were several measures included on the agenda for discussion and that February 20, 2026, was the last day to introduce bills. Dr. Crowley further noted that April 24, 2026, was the last day for policy committees to hear and report to fiscal committees bills keyed as fiscal; May 15, 2026, is the last day for fiscal committees to hear and report to the floor bills introduced in their house. Dr. Crowley highlighted the deadlines noting that the legislature is very early in the legislative cycle. Dr. Crowley indicated it may be appropriate to watch some measures through the first policy and appropriation committee hearings rather than establish a position.

Dr. Crowley added the meeting agenda and materials identified pending measures impacting the practice of pharmacy, the Board's jurisdiction, or Board operations that were identified during the development of the agenda for the meeting.

Members were provided the opportunity to comment; however, no comments were made.

a. Assembly Bill 910 (Bonta, 2025) Pharmacy Benefit Management

Dr. Crowley reported Assembly Bill 910 requires the Department of Health Care Access and Information (HCAI) to include prescription drug pricing and payment data in its annual health care report and to notify the Department of Managed Health Care (DMHC) if a pharmacy benefit manager (PBM) fails to comply with specified requirements. The measure also requires DMHC to post links on its website to analyses and reporting published by HCAI. The measure passed out of the Assembly with 71 votes in support, 2 in opposition, and 7 in abstention.

Dr. Crowley agreed with the recommendation to establish a support position.

Motion: Support

M/S: Serpa/Thibeau

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

b. Assembly Bill 957 (Ortega, 2025) Cigarette and Tobacco Products: Retail Sale: Pharmacies

Dr. Crowley advised Assembly Bill 957 would prohibit a pharmacy from selling cigarettes or tobacco products. The policy goals of the measure appear consistent with the Board's policy statement included in the meeting materials.

Dr. Crowley noted this is a two-year bill that was granted reconsideration in July 2025 by the Senate Business, Professions, and Economic Development Committee. The Board previously established a support position on this bill and believed that the position remained appropriate. Dr. Crowley further noted that the measure had not moved since reconsideration was granted last year.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Dong/Serpa

Members of the public participating from Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A commenter expressed support of the bill and emphasized that banning tobacco sales in pharmacies aligns with public health goals and removes conflicting messages in healthcare settings.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

c. Assembly Bill 1460 (Rogers, 2025) Prescription Drug Pricings

Dr. Crowley advised Assembly Bill 1460 would prohibit a prescription drug manufacturer from blocking or interfering with qualifying nonprofit community health clinics' ability to buy drugs at the reduced federal 340B price, under specified conditions.

Dr. Crowley noted this is a two-year bill that has been held at the Senate Health Committee. The Board previously established a support position on this bill.

Dr. Crowley believed the Board's current support position remained appropriate.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating from Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A commenter expressed concern regarding subsection F which would allow manufacturers to require additional information from 340B participants beyond what federal law requires which would significantly increase administrative costs, burden pharmacies, and undermine the 340B program, which manufacturers have long opposed. The commenter felt the amendment would harm patients and participating pharmacies and urged the Board to reconsider its position and refrain from supporting the bill.

Members were provided the opportunity to comment having heard public comments. Members noted that 340B program was critical to the public health safety net for patients and maintained a support position.

d. Assembly Bill 1558 (Arambula, 2026) Uniform Emergency Volunteer Health Practitioners Act

Dr. Crowley advised Assembly Bill 1558 would create the Uniform Emergency Volunteer Health Practitioners Act, establishing a statewide system to register out-of-state volunteer health practitioners—such as physicians, pharmacists, and veterinarians—to provide services during a declared emergency. The Emergency Medical Services Authority would administer the program and could limit the duration, location, or types of volunteer practice during an emergency.

Dr. Crowley noted the measure would allow the Board to restrict or modify the services a volunteer practitioner may provide and would also authorize the Board to impose administrative sanctions on in-state licensees for misconduct committed during an out-of-state emergency response, as well as on out-of-state practitioners for misconduct in California during an in-state emergency, provided certain conditions are met.

Dr. Crowley agreed with the staff's recommendation to establish a support, if amended position noting Board staff believed technical amendments are necessary to establish a feedback loop between the Emergency Medical Services Authority and the Department of Consumer Affairs/Board of Pharmacy to ensure that the Board is notified of licensees providing emergency medical services both within and outside of California.

Dr. Crowley noted the measure is currently awaiting consideration by the Assembly Appropriations Committee.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support if amended

M/S: Thibeau/Serpa

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

e. Assembly Bill 1587 (Ta, 2026) Prescription Drug Refills: Prescriber Notifications

Dr. Crowley advised Assembly Bill 1587 amends the conditions for pharmacist authority to provide emergency refills to specify that notification to a prescriber is only required if a prescriber is identified. Following the release of the Committee's meeting materials, the measure advanced out of the Assembly and was subsequently sent to the Senate.

Dr. Crowley agreed with the recommendation to establish a watch position.

Members were provided the opportunity to comment. Members discussed the reasoning behind the bill and agreed with a watch position.

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

f. Assembly Bill 1773 (Blanca Rubio, 2026) Pharmacy Benefit Managers.

Dr. Crowley advised Assembly Bill 1773 required the Department of Managed Health Care to maintain a public website displaying specified information for each licensed pharmacy benefit manager, including, among other things, the legal name, license number, and license expiration date. Dr. Crowley noted that following the release of the Committee's meeting materials, the measure was ordered to the Assembly Consent Calendar.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Crowley/Serpa

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

g. Assembly Bill 1775 (Ward, 2026) Veterans.

Dr. Crowley advised that Assembly Bill 1775 extended the current expedited licensing process for veterans to also cover service members who were discharged solely because of the federal action to restrict military service by transgender individuals, not just those who were honorably discharged. This measure is awaiting consideration by the Assembly Appropriations Committee.

Dr. Crowley agreed with the recommendation to establish a support position as the Board has historically supported measures that impact licensure access for military members, veterans, and military spouses.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Thibeau/Crowley

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

h. Assembly Bill 1778 (Patterson, 2026) Controlled Substances: Testosterone.

Dr. Crowley advised Assembly Bill 1778 removes testosterone from California's Schedule III controlled substances list automatically if the federal government removes it from its scheduled controlled substance list without requiring separate state legislation. Following release of the Committee meeting materials this measure passed out of the Assembly Public Safety Committee and was referred to Assembly Appropriations.

Dr. Crowley agreed with the recommendation to establish a watch position and noted that testosterone can be misused and abused and, as a result of AB 82 (Ward, Chapter 679, Statutes of 2025), is no longer reported to CURES. Dr. Crowley further noted that removing it from California's schedule could lead to overprescribing and increase the risk of misuse.

Members were provided the opportunity to comment. Members discussed considering a support position or amendment to address barriers to gender-affirming care, particularly for those using masculinizing medications like testosterone. They noted unequal access due to testosterone being a controlled substance and reported emerging difficulties for some Californians obtaining gender-affirming medications following recent federal actions.

Motion: Support

M/S: Thibeau/Crowley

Members of the public participating from Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A commenter noted concern of potential misuse if the substance is

unscheduled, noting that abuse risks are the same regardless of user group.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

i. Assembly Bill 1794 (Ransom, 2026) Pharmacy: Enteral Products.

Dr. Crowley advised Assembly Bill 1794 as amended authorizes a pharmacist, manufacturer, or wholesaler to participate in an arrangement or agreement to deliver enteral nutrition supplements or replacements directly to a patient's residence pursuant to a valid order from a prescriber acting within their scope of practice. The measure was being considered by the Assembly Appropriations Committee.

Dr. Crowley noted that Board staff are not offering a recommendation on the measure.

Members were provided the opportunity to comment. Members discussed the intent behind the bill and noted they wanted more information.

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

j. Assembly Bill 1811 (Rogers, 2026) Health Professional Shortage Areas.

Dr. Crowley advised Assembly Bill 1811 as amended defines "health professional shortage area" until January 1, 2035, to include areas designated by California's Department of Health Care Access and Information, areas federally designated by HHS, and those federally designated on January 1, 2025—even if no longer federally recognized. As such, this measure ensures areas proposed for withdrawal post-2025 remain eligible for state prioritization and benefits. This measure was currently awaiting consideration by the Assembly Appropriations Committee.

Dr. Crowley agreed with the recommendation to establish a support position and noted that the measure maintained current shortage areas and believed amendments to clarify its application to pharmacies as defined health professional shortage areas.

Members were provided the opportunity to comment. Members discussed why staff were recommending both support of the bill and proposing amendments. Staff explained they believed the policy was beneficial regardless, but clarification was still needed on whether it applies to pharmacies; if not, they would request a technical amendment. Members discussed how shortage-area designations may or may not include pharmacists and noted that the bill could still indirectly affect pharmacies through related programs like 340B.

Motion: Support

M/S: Thibeau/Serpa

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

k. Assembly Bill 1854 (Krell, 2026) Legally Protected Health Care Activities.

Dr. Crowley advised Assembly Bill 1854 as amended stops California agencies and law enforcement from helping other states with arrests, information requests, or investigations related to certain protected health care services, such as reproductive care or gender-affirming care. It also blocks subpoenas, warrants, and other legal requests from other states, except in very limited situations. Dr. Crowley noted the measure was awaiting consideration by the Assembly Appropriations Committee.

Dr. Crowley agreed with the recommendation to establish a support position.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Thibeau/Dong

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

I. Assembly Bill 1930 (Zbur, 2026) Legally Protected Health Care Activity: Inquiries, Investigations, Subpoenas, or Summons.

Dr. Crowley advised Assembly Bill 1930 as amended would stop any person or business in California from giving information to another state about legally protected health care activities unless specified conditions are met, including that the request must include an affidavit stating under penalty of perjury that the investigation involves an act that is actually illegal under California law, and it must identify the specific California law that was violated. Dr. Crowley noted that following the release of the Committee's meeting materials the measure passed out of the Assembly Public Safety Committee and was referred to the Assembly Appropriations Committee.

Dr. Crowley agreed with the recommendation to establish a support position.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Thibeau/Serpa

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

m. Assembly Bill 1979 (Bonta, 2026) Health Care Services: Artificial Intelligence.

Dr. Crowley advised Assembly Bill 1979 was amended following the release of the Committees meeting materials. The policy goals of the measure remain the same, ensuring that a licensed health care professional working in a health facility, clinic, physician's office, or office of a group practice, exercise independent professional judgement when reviewing and approving clinical decisions that are based on the output from a clinical decisions support system. Additionally, it authorizes the appropriate licensing board to seek an injunction or restraining order when violations amount to the unlicensed practice of a health profession. The measure clarifies that the restrictions do not prohibit the use of artificial intelligence for non-clinical tasks that do not require professional judgment, such as documentation or automated patient notifications. Dr. Crowley noted that following release of the Committee's meeting materials the measure passed out of the Assembly Privacy and Consumer Protection Committee and was referred to Assembly Appropriations.

Dr. Crowley further noted that as amended, the measure does not apply to pharmacies and other unlicensed areas where pharmacists and advanced pharmacist practitioners may work, including, for example, pharmacies and ambulatory care settings. Dr. Crowley believed that the prohibitions should be extended to all practice sites where health care providers, including pharmacists, are providing patient care services.

Dr. Crowley noted that the Board raised concerns with the use of AI as part of its 2025 Sunset Report and that “while the Board does not believe a total prohibition on the use of AI in pharmacy practice is either necessary or in the best interest of patients, and while the Board believes that AI is a tool to assist a pharmacist in making a clinical judgement, the Board stands firm that AI cannot and should not supplant such clinical judgement.” The policy goals of the measure aligns with the Board's position.

Dr. Crowley agreed with the recommendation to establish a support if amended position and recommend offering an amendment to ensure the requirements extend to all pharmacist and advanced pharmacist practitioner sites.

Members were provided the opportunity to comment. Members discussed national conversations and that some states are moving to bypass physicians and pharmacists to allow AI to approve refill prescriptions.

Motion: Support if amended

M/S: Serpa/Thibeau

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

- n. Assembly Bill 1990 (Gipson, 2026) Pharmacy Law: Compounded Medications: Consumer Protection.

Dr. Crowley advised following release of the meeting materials, this measure was amended. As amended, the measure continues to declare legislative concerns about unsafe or illicit active pharmaceutical ingredients entering the

compounding supply chain, particularly amid high demand for weight-loss drugs. It prohibits selling or distributing compounded drugs containing certain GLP-1 or related substances used for obesity or weight management unless the compounder takes specified actions, including ensuring that the bulk drug substance is a pharmaceutical grade product and meets specified requirements. Manufacturers and wholesalers must also provide written verification to purchasers that bulk drug substances sold for this purpose meet specified requirements. The bill makes violation of its provisions subject to license revocation and fines of \$1,000 per dose of the illegally compounded drug sold, transferred, or distributed. The measure further requires specified recordkeeping, authorizes Board inspections of compounders and suppliers, and prohibits misleading advertising of compounded weight-management drugs.

Dr. Crowley noted the bill's provisions do not apply to physicians and surgeons and the recent amendments update the proposed disclosure requirements regarding potential side effects, adverse reactions and other warnings associated with active ingredients in the medication, unless the advertiser can demonstrate that a particular disclosure is not relevant to the compounded drug.

Dr. Crowley further noted that the measure did not apply uniformly across all settings where GLP-1 compounding occurs, such as physician offices and medical spas.

Dr. Crowley advised that Board staff have encountered significant patient safety issues in these environments during inspections and investigations, but often lack the authority to intervene, and staff believe patient-safety gaps will persist unless the requirements apply to all compounding and advertising settings. Staff had expressed concern about the bill's mandatory penalties—\$1,000 per dose and license revocation—which removes the Board's discretion to evaluate cases and determine appropriate enforcement consistent with its consumer-protection mandate.

Dr. Crowley further noted that some requirements in the bill already exist under federal law, USP standards, or existing Board regulations, while others go beyond current standards. Following release of the meeting materials, the measure passed out of the Assembly Privacy and Consumer Protection Committee and was referred to the Assembly Appropriations Committee.

Dr. Crowley agreed with the recommendation to establish a watch position and believed it was appropriate for Board staff to engage with the author's office to seek to address the concerns and issues raised.

Members were provided the opportunity to comment. Members discussed the fiscal impacts and noted that while the concept of ensuring appropriate compounding is sound, the bill focused on a single product for political or commercial reasons and conflicted with existing board regulations, federal laws, and established compounding standards. Members expressed concern that it undermines both the Board's authority and pharmacists' professional judgment and supporting the bill would contradict the Board's extensive work on state compounding regulations and appeared to benefit manufacturers more than patients. Members agreed with the staff recommendation to watch the bill for now.

Members of the public participating from Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. Multiple commenters expressed strong concerns about the bill's impact on compounding. Several noted that existing USP standards and state regulations already provide robust quality and safety requirements, and the bill would create conflicting or overly burdensome standards that could make legitimate compounding impossible for many pharmacies. Commenters warned that required API testing would be cost-prohibitive, could force pharmacies out of the market, and ultimately limit patient access to needed individualized medications. Others emphasized that the bill appeared to disproportionately benefit drug manufacturers, targets pharmacies while exempting physicians who compound in office settings, and risks creating overlapping or confusing regulatory requirements. Some commenters supported stronger safety controls for GLP-1 compounding given increased scale and impurity concerns.

Members were provided the opportunity to comment having heard public comments. Members appreciated the comments and reiterated concerns about targeting a single drug class, noting that GLP-1 medications have important uses beyond weight loss and cautioned that isolating one drug class could set a problematic precedent, especially given the extensive work already done to

create comprehensive compounding regulations. Members noted that national concerns raised by supporters of the bill may not apply equally in California, which has stronger regulations. Staff will reach out to the author's office for clarification.

o. Assembly Bill 2000 (Aguilar-Curry, 2026) Drug Formularies.

Dr. Crowley advised Assembly Bill 2000 as amended bans health plans, insurers, and PBMs from changing their drug formularies during the plan year except in limited circumstances. If a change would force a patient to switch medications, the patient may continue their originally approved and safe drug for the remainder of the year. The measure also requires 90-day advance notice before any changes, mandates reporting changes to the state within 30 days, and authorizes state agencies to audit, investigate, and penalize entities that fail to comply. This measure is awaiting action by the Assembly Appropriations Committee.

Dr. Crowley noted that, as currently drafted, the measure allowed modification of a drug formulary to remove a drug due to safety concerns raised by the United States Food and Drug Administration (FDA) and that there are other reliable sources outside of the FDA.

Dr. Crowley agreed with the recommendation to establish a support if amended position and recommended offering an amendment to include other reliable resources.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support if amended

M/S: Thibeau/Crowley

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

- p. Assembly Bill 2141 (Patterson, 2026) Pharmacies: License Discipline: Stipulated Settlement and Disciplinary Order.

Dr. Crowley advised Assembly Bill 2141 as amended authorized the Board and a licensee to enter into a stipulated settlement and disciplinary order before a formal accusation is filed, provided certain conditions are met, including the licensee voluntarily waiving administrative hearing rights under the Administrative Procedure Act and submitting specified mitigation and rehabilitation information. Dr. Crowley further advised that a designated Board committee must review the information and is permitted to extend a stipulated settlement and disciplinary order offer to the licensee. Dr. Crowley noted the measure is awaiting consideration by the Assembly Appropriations Committee.

Dr. Crowley noted that, between 2019 and 2021, the Board explored creating an alternative enforcement model to improve the efficiency of its disciplinary process but never finalized development of a proposal because, at the request of stakeholders, the Board stopped its consideration of the matter in July 2021.

Dr. Crowley agreed with the recommendation not to establish a position on this measure.

Members were provided the opportunity to comment. Members expressed disappointment that the issue moved into the legislative process after the Board had already invested significant time working with stakeholders and the Attorney General's office on an alternative enforcement model and then stakeholders unexpectedly asked the board to halt its efforts.

Members of the public participating from Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A commenter provided background and requested the Committee support the bill.

Members were provided the opportunity to comment having heard public comments. Members clarified that most enforcement issues are resolved during inspections through corrections, orders of correction, or citations, and only the most serious violations proceed to discipline noting that minor errors do not automatically become disciplinary matters and that the Board's focus is on education and compliance.

The Committee took a break from 10:42 a.m. to 11:00 a.m.

q. Assembly Bill 2282 (Alanis, 2026) Health Facilities: Emergency Medical Services.

Dr. Crowley advised Assembly Bill 2282 allowed a general acute care hospital to get a special permit to operate an emergency stabilization unit in Patterson, Stanislaus County, a separate location not connected to the main hospital, to serve the community previously served by Del Puerto Health Care District. The measure was awaiting consideration by the Assembly Appropriations Committee.

Dr. Crowley agreed with the recommendation not to establish a position on this measure as well as the recommendation to offer technical amendments to ensure the Board will have the authority to issue a pharmacy license to an emergency stabilization unit if needed.

Members were provided the opportunity to comment. Members agreed with the position.

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

r. Assembly Bill 2565 (Wallis, 2026) Medi-Cal: Pharmacist Services: Reporting.

Dr. Crowley advised following release of the meeting materials, Assembly Bill 2565 was amended. As amended, Assembly Bill 2565 requires the Department of Health Care Services to issue guidance clarifying Medi-Cal managed care plans' obligations to cover pharmacist services and directs DHCS to update its model

Evidence of Coverage to explicitly state that pharmacist services are covered. DHCS must also take corrective action if plans fail to comply with existing pharmacist-service coverage requirements or the new guidance. The measure authorizes DHCS to implement these provisions through all-plan letters, plan letters, or similar instructions without needing to go through the formal regulatory process.

Dr. Crowley noted the measure was awaiting consideration by the Assembly Appropriations Committee.

Dr. Crowley believed the Board should establish a support position on the measure.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Crowley/Thibeau

Members of the public participating from Sacramento and were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative of CPhA provided background information on the issue and urged the Board to support the bill to help address barriers and advance pharmacy practice in California.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

s. Assembly Bill 2571 (Flora, 2026) Reimbursement for Pharmacist Services.

Dr. Crowley advised Assembly Bill 2571 requires that advanced pharmacist practitioners be paid at the same rate as physicians under Medi-Cal (100% of the physician fee schedule, instead of the current 85%).

Dr. Crowley noted that this measure is similar to AB 1366 on which, through the delegated authority given to the Board president, the Board had established a support position. The measure passed through the Assembly and was pending with Senate Rules for assignment.

Dr. Crowley agreed with the recommended support position for this measure.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Thibeau/Crowley

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

t. Senate Bill 915 (Menjivar, 2026) Health Care Provider Entities: Patients Accompanied by Immigration Enforcement Officers.

Dr. Crowley advised Senate Bill 915 as amended required health care provider entities to verify and document the identity and agency of any immigration enforcement officer who accompanies a patient. Staff must ask the officer to step out during medical discussions or treatment (with limited exceptions) and

the officer is prohibited from making or influencing medical decisions. If an officer refuses to comply, staff must report such refusal to management or legal counsel, who must document the incident and, if possible, record the officer's name and badge number. The measure also establishes requirements for care transitions and discharge planning consistent with state and federal law.

Dr. Crowley noted that the measure passed out of the Senate Judiciary Committee with amendments on April 21. Legal counsel confirmed the amendments clarified that if a health care provider request the immigration officer leave and the officer doesn't leave, the health care provider would document the incident, and that had fulfilled their duty.

Dr. Crowley noted support of the concept but needed to ensure patient autonomy and privacy.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Dong/Thibeau

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

u. Senate Bill 964 (Smallwood-Cuevas, 2026) Prescription Drug Coverage: Dose Adjustments.

Dr. Crowley advised, as amended, Senate Bill 964 enables a patient's treating provider to adjust patient medication doses or dosing frequency without seeking

prior authorization from health plans or insurers, under specified conditions. The measure was on the Senate Appropriations Committee Suspense file.

Dr. Crowley agreed with the recommended support position for this measure.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Thibeau/Serpa

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

v. Senate Bill 1023 (Laird, 2026) Health Care Coverage: Antiretroviral Drugs, Drug Devices, and Drug Products.

Dr. Crowley advised Senate Bill 1023 prohibits health care service plans (except Medi-Cal managed care plans) and health insurers from requiring prior authorization or step therapy for medically necessary PrEP or PEP, but allows them to apply these restrictions to other therapeutically equivalent versions as long as one option is available without restriction.

Senate Bill 1023 removes that exception and fully prohibits prior authorization or step therapy for all antiretroviral drugs, devices, or products used for HIV prevention. Beginning January 1, 2027, any plan that covers FDA-approved, non-self-administered HIV prevention treatments as a medical benefit must also cover them as an outpatient prescription drug benefit.

Dr. Crowley noted that this measure is similar to AB 554, which the Governor vetoed, but differs in scope. AB 554 broadly addressed coverage and access requirements for all antiretroviral drugs used for HIV treatment and prevention, while this bill focuses narrowly on resolving a specific reimbursement issue for injectable, long-acting PrEP by creating a workable billing pathway for clinics. The Board had a support position for AB 554.

Dr. Crowley noted the measure was also on the Senate Appropriations Committee suspense file.

Dr. Crowley agreed with the recommended support position for this measure.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Crowley/Dong

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 3

Oppose: 0

Abstain: 1

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Abstain

w. Senate Bill 1094 (Weber Pierson, 2026) Prescription Drugs.

Dr. Crowley advised, as amended, Senate Bill 1094 would allow a pharmacist to substitute a biosimilar drug (a nearly identical version of a brand-name biologic drug) when filling a prescription; as long as the prescription does not include “do not substitute” or words of similar meaning, as specified. Dr. Crowley noted that following release of the Committee meeting materials the measure passed out of the Senate Health Committee and would be considered by the Senate Appropriations Committee on May 4.

Dr. Crowley noted that current law grants a pharmacist the authority to select an interchangeable biological product, and the measure expands these provisions to allow a pharmacist to select a biosimilar product.

Dr. Crowley agreed with the recommended watch position for this measure.

Members were provided the opportunity to comment. Members discussed the reasoning for a watch position rather than a support position.

Members of the public participating from Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating from Sacramento were provided the opportunity to comment. The Committee heard a comment supporting adding “biosimilar” to the Business and Professions Code, noting it aligns with current pharmacy practice and existing formulary and contracting processes. However, the commenter opposed the bill due to concerns with the insurance-related provisions. A representative from CHpA noted support of the bill’s overall intent to broaden biosimilar use but raised concerns about potential vertical integration and patient steering and noted they would support the bill if amended to ensure pharmacists can appropriately participate in the process and protect patient interests. The commenter also emphasized the importance of avoiding unintended consequences related to insurance or supply-chain consolidation.

x. Senate Bill 1199 (Weber Pierson, 2026) Prescription Drug Cost Sharing.

Dr. Crowley advised, Senate Bill 1199 required plans and insurers to count *all* payments made by or on behalf of an enrollee, including permitted manufacturer assistance, toward their out-of-pocket maximum and other cost-sharing requirements. It also establishes an administrative penalty for each violation by a health insurer, enforceable by the Insurance Commissioner after notice and an opportunity for a hearing.

Dr. Crowley noted that this measure appeared to be designed to benefit patients by ensuring that any financial assistance they receive toward prescription drugs, such as manufacturer copay coupons or third-party assistance, counts toward their in-network deductible and out-of-pocket

maximum. Dr. Crowley further noted that following release of the Committee meeting materials the measure passed out of the Senate Health Committee and was referred to Senate Appropriations.

Dr. Crowley agreed with the recommended support position for this measure.

Members were provided the opportunity to comment. Member expressed support for taking a support position on the bill, emphasizing its importance for patients with high-cost conditions such as HIV and noted that many patients rely on manufacturer assistance programs, which can cover large portions of deductibles, yet patients often never fully meet their deductible or only meet it late in the year before it resets.

Motion: Support

M/S: Thibeau/Crowley

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

y. Senate Bill 1347 (Niello, 2026) Pupil Health: Emergency Stock Albuterol Inhalers.

Dr. Crowley advised existing law allowed schools to stock emergency albuterol inhalers and permitted school nurses or trained volunteers to use them to assist individuals experiencing respiratory distress. As amended, Senate Bill 1347 expands that program to include childcare programs operated by or contracting with a school district, county office of education, or charter school. Dr. Crowley noted the measure remained on the Senate Third Reading File.

Dr. Crowley further noted that the measure's provisions appeared only in the Education Code, which may limit pharmacies' awareness that they can legally dispense inhalers under these provisions. Board staff suggest making technical amendments to also reference this authority in Pharmacy Law, similar to existing cross-references for emergency epinephrine and naloxone (Business and Professions Code §§ 4119.2 and 4119.8). Dr. Crowley noted that adding a parallel provision in Pharmacy Law could help ensure pharmacies clearly understand their authority to furnish emergency albuterol inhalers to schools and childcare programs.

Dr. Crowley agreed with the recommended support position and the staff-recommended technical amendments for this measure.

Members were provided the opportunity to comment; however, no comments were made.

Motion: Support

M/S: Dong/Serpa

Members of the public participating from Sacramento and via Webex were provided the opportunity to comment; however, no comments were made.

Support: 4

Oppose: 0

Abstain: 0

Not Present: 2

Board Member	Vote
Chandler	Not Present
Crowley	Support
Dong	Support
Jha	Not Present
Serpa	Support
Thibeau	Support

V. Discussion and Consideration of Board Regulations

Dr. Crowley advised all items included in the regulations portion of the report were for information only. Dr. Crowley noted as detailed in the meeting materials and associated attachments, the Board had several regulations in various stages of promulgation. The Board had one regulation undergoing a 45-day comment period, four regulations undergoing pre-notice review, staff are revising or preparing regulation documents for two regulations, three regulations have been withdrawn

from the Office of Administrative Law (OAL), and one package was approved by OAL.

Members were provided the opportunity to comment; however, no comments were made.

Members of the public participating from Sacramento were provided the opportunity to comment; however, no comments were made.

Members of the public participating via Webex were provided the opportunity to comment. A representative of CPhA noted that document C regarding advanced pharmacist practitioner still states as advanced practice pharmacist.

VI. Future Committee Meeting Dates

Chairperson Crowley advised the next Committee meeting date was scheduled for June 11, 2026, and encouraged participants to watch the Board's website for updates.

VII. Adjournment

Chairperson Crowley adjourned the meeting at 11:32 a.m.